Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plasminogen intravenous - Liminal BioSciences

Next Previous
X
Search
Drug Profile

Plasminogen intravenous - Liminal BioSciences

Alternative Names: Ryplazim; Ryplazima

Latest Information Update: 06 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProMetic Life Sciences
  • Developer Kedrion; Liminal BioSciences
  • Class Anti-inflammatories; Antifibrotics; Antithrombotics; Beta-globulins; Blood products and substitutes; Proteins
  • Mechanism of Action Fibrinolytic agents; Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Type I plasminogen deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type I plasminogen deficiency
  • No development reported Acute lung injury; Idiopathic pulmonary fibrosis; Wounds

Most Recent Events

  • 29 Apr 2024 Launched for Type I Plasminogen Deficiency (In adolescents, In children, In adults) in USA (IV)
  • 29 Apr 2024 Liminal BioSciences announces intention to launch Plasminogen intravenous for the treatment of Type I Plasminogen Deficiency in the US, in 2022
  • 28 Jan 2022 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Canada (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top